

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48		A1	(11) International Publication Number: WO 99/34833 (43) International Publication Date: 15 July 1999 (15.07.99)
(21) International Application Number: PCT/US99/00594		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 6 January 1999 (06.01.99)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 60/070,680 7 January 1998 (07.01.98) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/070,680 (CON) Filed on 7 January 1998 (07.01.98)			
(71) Applicant (for all designated States except US): SEAWATER POLYMERS, INCORPORATED [US/US]; 1112 Church Street, Huntsville, AL 35801 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): HARRIS, J., Milton [US/US]; 3119 Highland Plaza, Huntsville, AL 35801 (US). ZHAO, Xuan [CN/US]; 2805 Southhurst Drive, Huntsville, AL 35803 (US).			
(74) Agents: PEDIGO, Paul, F. et al.; Alston & Bird LLP, P.O. Drawer 34009, Charlotte, NC 28234-4009 (US).			
(54) Title: DEGRADABLE HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) ACRYLATES AND GELS AND CONJUGATES DERIVED THEREFROM			
(57) Abstract			
<p>A heterobifunctional poly(ethylene glycol) is provided having a hydrolytically degradable linkage, a first terminus comprising an acrylate group, and a second terminus comprising a target such as a protein or pharmaceutical agent or a reactive moiety capable of coupling to a target. Hydrogels can be prepared. The hydrogels can be used as a carrier for a protein or a pharmaceutical agent that can be readily released in a controlled fashion.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DEGRADABLE HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL)
ACRYLATES AND GELS AND CONJUGATES DERIVED THEREFROM

5

FIELD OF THE INVENTION

This invention relates to heterobifunctional poly(alkylene oxides) having degradable linkages and to conjugates derived therefrom.

BACKGROUND OF THE INVENTION

10 In its most common form, the poly(alkylene oxide) poly(ethylene glycol) (PEG) is a linear polymer terminated at each end with hydroxyl groups:



This polymer can be represented in a brief form as HO-PEG-OH where it is understood that -PEG- represents the following structural unit:




15 where n typically ranges from approximately 10 to 2000.


PEG is of great utility in a variety of biotechnical and pharmaceutical applications, particularly for drug delivery and modification of drug surfaces to promote nonfouling characteristics.

20 PEG is not toxic, does not tend to promote an immune response, and is soluble in water and in many organic solvents. The PEG polymer can be covalently attached to insoluble molecules to make the resulting PEG-molecule conjugate soluble. For example, Greenwald, Pendri and Bolikal in *J. Org. Chem.*, 60, 331-336 (1995) recite that the water-insoluble drug taxol, when coupled to PEG, becomes 25 water soluble. Davis et al. in U.S. patent 4,179,337 recite that proteins coupled to PEG have an enhanced blood circulation lifetime because of a reduced rate of kidney clearance and reduced immunogenicity. The lack of toxicity of the polymer and its rate of clearance from the body are important considerations in pharmaceutical applications. Pharmaceutical applications and many leading references are described 30 in the book by Harris (J. M. Harris, Ed., "Biomedical and Biotechnical Applications of Polyethylene Glycol Chemistry, Plenum, New York, 1992").

PEG is commonly used as methoxy-PEG-OH, or mPEG in brief, in which one terminus is the relatively inert methoxy group, while the other terminus is a hydroxyl group that is subject to ready chemical modification




PEG is also commonly used in branched forms that can be prepared by
5 addition of ethylene oxide to various polyols, including glycerol, pentaerythritol and
sorbitol. For example, the four-armed branched PEG prepared from pentaerythritol is
shown below:



10

The branched PEGs can be represented in a general form as
 $\text{R}(-\text{PEG-OH})_n$ in which R represents the central core molecule, which can include,
e.g., glycerol or pentaerythritol, and n represents the number of arms.

Often it is necessary to use an "activated derivative" of PEG to couple
15 PEG to a molecule. The hydroxyl group located at the PEG terminus, or other group
subject to ready chemical modification, is activated by modifying or replacing the
group with a functional group suitable for reacting with a group on another molecule,
including, e.g., proteins, surfaces, enzymes, and others. For example, the
succinimidyl "active ester" of carboxymethylated PEG forms covalent bonds with
20 amino groups on proteins as described by K. Iwasaki and Y. Iwashita in U.S. Patent
No. 4,670,417. The synthesis described in U.S. Patent No. 4,670,417 is illustrated
below with the active ester reacting with amino groups of a protein in which the
succinimidyl group is represented as NHS and the protein is represented as PRO-NH₂:



Succinimidyl "active esters", such as PEG-OCH₂-CO₂-NHS, are commonly used
forms of activated carboxylic acid PEGs, and they are prepared by reacting carboxylic
acid PEGs with N-hydroxysuccinimide.

30 PEG hydrogels, which are water-swollen gels, have been used for
wound covering and drug delivery. PEG hydrogels are prepared by incorporating the
soluble, hydrophilic polymer into a chemically crosslinked network or matrix so that
addition of water produces an insoluble, swollen gel. Substances useful as drugs

typically are not covalently attached to the PEG hydrogel for *in vivo* delivery. Instead, the substances are trapped within the crosslinked matrix and pass through the interstices in the matrix. The insoluble matrix can remain in the body indefinitely, and control of the release of the drug typically can be somewhat imprecise.


5 One approach to preparation of these hydrogels is described by Embrey and Grant in U.S. Patent No. 4,894,238. The ends of the linear polymer are connected by various strong, nondegradable chemical linkages. For example, linear PEG is incorporated into a crosslinked network by reacting with a triol and a diisocyanate to form hydrolytically stable urethane linkages that are nondegradable in
10 water.

A related approach for preparation of PEG hydrogels has been described by Gayet and Fortier in *J. Controlled Release*, 38, 177-184 (1996) in which linear PEG was activated as the p-nitrophenylcarbonate and crosslinked by reaction with a protein, bovine serum albumin. The linkages formed are hydrolytically stable
15 urethane groups and the hydrogels are nondegradable in water.

In another approach, described by N.S. Chu in U.S. Patent No. 3,963,805, nondegradable PEG networks have been prepared by random entanglement of PEG chains with other polymers formed by use of free radical initiators mixed with multifunctional monomers. P.A. King described nondegradable
20 PEG hydrogels in U.S. Patent No. 3,149,006 that have been prepared by radiation-induced crosslinking of high molecular weight PEG.

Nagaoka et al. described in U.S. Patent No. 4,424,311 preparing PEG hydrogels by copolymerization of PEG methacrylate with other comonomers such as methyl methacrylate. Vinyl polymerization produces a polyethylene backbone with
25 PEG attached. The methyl methacrylate comonomer is added to give the gel additional physical strength.

Sawhney et al. described, in *Macromolecules*, 26, 581 (1993) and U.S. Patent No. 5,626,863, the preparation of block copolymers of polyglycolide or polylactide and PEG that are terminated with acrylate groups:



where R is CH_3 - or H.

In the above formula, the glycolide blocks are the -OCH₂-CO- units; addition of a methyl group to the methylene group gives rise to a lactide block; n can be multiples of 2. Vinyl polymerization of the acrylate groups produces an insoluble, crosslinked gel with a polyethylene backbone. The polylactide or polyglycolide segments of the polymer backbone shown above, which are ester groups, are susceptible to slow hydrolytic breakdown, with the result that the crosslinked gel undergoes slow degradation and dissolution. While this approach provides for degradable hydrogels, the structure provides no possibility of covalently attaching proteins or other drugs to the hydrogel for controlled release. Applications of these hydrogels in drug delivery are thus restricted to release of proteins or other drugs physically entrapped within the hydrogel, thus reducing the potential for advantageous manipulation of release kinetics.

10 Hubbell, Pathak, Sawhney, Desai, and Hill (U.S. Patent 5,410,016, 1995) polymerized:

15 Protein-NH-PEG-O₂C-CH=CH₂

with long wavelength uv radiation to obtain a PEG acrylate polymer with a protein linked to it. The link between the PEG and the protein was not degradable, so the protein could only be hydrolytically released with PEG attached. Since the acrylate 20 polymer is not hydrolytically degradable, the release of the PEG protein derivative is not controllable.

25 Yang, Mesiano, Venkatasubramanian, Gross, Harris and Russell in *J. Am. Chem. Soc.* 117, 4843-4850, (1995) described heterobifunctional poly(ethylene glycols) having an acrylate group on one terminus and an activated carboxylic acid on the second terminus. They demonstrated the attachment of this PEG derivative to a protein and incorporation of the resulting PEG protein derivative into an acrylate polymer. However, the PEG backbone there is not degradable and the protein was thus, in effect, permanently bound to the acrylate polymer.

30 SUMMARY OF THE INVENTION

This invention provides heterobifunctional acrylates of poly(alkylene oxides), especially poly(ethylene glycol) (PEG) acrylates having linkages that are hydrolytically degradable and conjugates prepared from these acrylates having target materials such as proteins covalently linked thereto. Hydrogels can also be prepared

from these acrylates. The target materials can be released from the hydrogels through controllable hydrolytic degradation of the hydrogels.

In one embodiment of the invention, heterobifunctional PEG is provided which is represented by the formula:

5



where Z is an alkyl group or hydrogen atom, W is a hydrolytically unstable linkage comprising a hydrolyzable covalent bond, and Q is a reactive moiety capable of reacting with a target to form a covalent linkage thus linking the PEG polymer to the target.

10

In another embodiment, this invention also provides a heterobifunctional PEG with a hydrolyzable linkage W in the PEG backbone and having an acrylate group at one terminus and a reactive moiety Q at the other terminus. The heterobifunctional PEG is represented by the formula of:




15

where Z is an alkyl group or hydrogen atom, W is a hydrolytically unstable linkage comprising a hydrolyzable bond, and Q is a reactive moiety capable of reacting with a moiety on a target such as protein or a drug.

The present invention also encompasses a conjugate having a formula of:

20



where Z and W are as described above, T is a target, e.g., a protein or a drug, L is a covalent linkage formed in the reaction between Q and a reactive moiety of T, and x is a number from 1 to 10.

25

In yet another embodiment of the invention, a conjugate of heterobifunctional PEG and a target is provided having the formula



30

where Z and W are as described above, T is a target, e.g., a protein or a drug, which is linked to the PEG polymer as a result of the reaction between the reactive moiety Q and a moiety on T, L is a covalent linkage formed in the reaction between Q and a reactive group of T, and x is a number of from 1 to 10.

This invention further provides polymers formed by vinyl polymerization of the aforementioned heterobifunctional PEG or conjugates thereof, represented by the formula: $\text{CH}_2=\text{CZ-CO}_2\text{-PEG-W-Q}$, $(\text{CH}_2=\text{CZ-CO}_2\text{-PEG-W-L})_x\text{-T}$, $\text{CH}_2=\text{CZ-CO}_2\text{-PEG-W-PEG-Q}$, and $(\text{CH}_2=\text{CZ-CO}_2\text{-PEG-W-PEG-L})_x\text{-T}$. The weak

chemical linkages in the thus formed polymers provide for hydrolytic breakdown and concomitant release of bound target molecules. For example, polymerization of the above-mentioned conjugate:




5 yields a water-soluble acrylate polymer which upon hydrolytic degradation liberates a smaller PEG fragment bearing a target such as a protein or a drug.

In another embodiment of the invention, hydrogels are formed by copolymerizing a heterobifunctional PEG conjugate of this invention with a PEG molecule having two or more acrylate groups ("PEG multiacrylate"). Exemplary 10 examples of such PEG multiacrylate can be:



or



The hydrogel of the present invention is a cross-linked network in which protein or 15 other target molecules are covalently bound to a degradable matrix. Because of the hydrolytically unstable linkages W in the hydrogels, the target molecules such as drug or protein molecules can be released as a result of the breakdown of the unstable linkages.

In the heterobifunctional PEG, polymers, and hydrogels of the present 20 invention, the hydrolytic breakdown of the hydrolytically unstable linkages W can be controlled in part by varying W, in particular the number of methylene group proximate to the hydrolyzable bond in W. Specifically, as the number of methylene group increases, the hydrolysis rate of the hydrolyzable bond of W decreases.

Further, in the hydrogel of the present invention, the release rate of the 25 target from the hydrogel can also be controlled by varying the number x in the above formula of the PEG conjugate, i.e., the number of the PEG acrylate linked to the target. The release rate of the target from the hydrogel is decreased when the number of PEG acrylate linked to the target is increased, and vice versa.

Thus, the present invention provides heterobifunctional PEG and 30 hydrogels formed therefrom having target molecules covalently linked to the hydrogels. In contrast to the PEG hydrogels known heretofore in the art, the target molecules can be released in a controlled fashion from the PEG hydrogels of the present invention. Further, since the release rate of the target can be determined by both the number of the attached PEG and the structure of the hydrolytically unstable

linkage in the attached PEG, more precise control of the release kinetics is made possible. Therefore, suitable drug carriers for drug delivery which meet different drug release requirements can be made in accordance with the present invention.

The foregoing and other advantages and features of the invention, and 5 the manner in which the same are accomplished, will become more readily apparent upon consideration of the following detailed description of the invention taken in conjunction with the accompanying examples, which illustrate preferred and exemplary embodiments.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a plot of the release profile of lucifer-yellow lysozyme from a PEG acrylate hydrogel.

DETAILED DESCRIPTION OF THE INVENTION

15 A heterobifunctional water soluble and hydrolytically degradable polymer is provided comprising a polymer backbone having a degradable linkage, a first terminus comprising an acrylate group, and a second terminus comprising a target or a functional group capable of coupling the polymer to a target.

20 As used herein, the terms "group," "moiety," "site," and "radical" are all somewhat synonymous and are used herein to refer to distinct, definable portions or units of a molecule or units that perform some function or activity or reactive with other molecules or portions of molecules.

25 The term "linkage" is used herein to refer to groups that normally are formed as the result of a chemical reaction and typically are covalent linkages.


Hydrolytically stable linkages means that the linkages are stable in water and do not react with water at useful pHs for an extended period of time, potentially indefinitely. Hydrolytically unstable linkages are those that react with water, typically causing degradation of a hydrogel and release of substances trapped within the matrix. The linkage is said to be subject to hydrolysis and to be hydrolyzable. The time it takes to 30 degrade the crosslinked polymeric structure is referred to as the rate of hydrolysis and is usually measured in terms of its half life. Thus, in the present invention, the target molecules typically are released at a predetermined rate or within a predetermined time.

"Heterobifunctional" refers to the first and second terminii on the polymer, one of which is acrylate, and the other of which is the target molecule or or functional group capable of coupling the polymer to a target.

A preferred embodiment of the heterobifunctional polymer is
5 represented by the formula:



Another preferred embodiment is represented by the formula:



In the above formulas, Z can be H or an alkyl group. Preferably, the
10 alkyl group has less than 20 carbon atoms, more preferably less than 10 carbon atoms, and most preferably less than 3 carbon atoms.

Typically, the polymer backbone represented by POLY and POLY' are
poly(alkylene oxide), including derivatives thereof. A suitable poly(alkylene oxide)
or derivative thereof can comprise a group represented by the formula
15 $-(\text{CH}_2\text{CHRO})_n\text{-CH}_2\text{CHR-}$ in which R is H or an alkyl group, and n ranges from about
10 to about 4000. Preferably, R is H and the polymer backbone comprises a
poly(ethylene glycol) group. Poly(ethylene glycol) is preferred because it is
substantially non-toxic and non-immunogenic.


W is a hydrolytically unstable linkage that can break down in an
20 aqueous environment by hydrolysis. Typically, the linkage W comprises a
hydrolyzable covalent bond. Suitable examples of such hydrolyzable covalent bonds
include, but are not limited to, carboxylate esters, imines, phosphate esters, acetals,
orthoesters, peptide bonds, and oligonucleotides.

These hydrolyzable bonds can be formed by reaction of pairs of
25 reactive moieties, for example, alcohol and carboxylic acid reacting to form
carboxylate esters, amine and aldehyde reacting to form imines, hydrazide and
aldehyde reacting to form hydrazones, alcohol and phosphate reacting to form
phosphate ester, aldehyde and alcohol reacting to form acetals, alcohols and formate
reacting to form orthoesters, amino acid and amino acid reacting to form peptide
30 bonds, nucleotide and nucleotide to form oligonucleotide bonds.

Typically the hydrolytically degradable linkage W further comprises a
plurality of alkylene groups, preferably methylene groups, proximate to the
hydrolyzable bond. The rate of degradation of the hydrolytically degradable linkage


W by hydrolysis is in part determined by the number of the alkylene groups and the distance of these groups from the hydrolyzable bond.

In a preferred embodiment, W has the structure of:



5

or



where m ranges from 1 to 10 and R₁ is selected from the group consisting of -CH₂-, -CH₂CH₂-, and -CH(CH₃)CH₂-. In these two examples, the rate of hydrolysis of the ester linkage increases with a decreasing value of m.

10

In the heterobifunctional polymer of the above formula, Q is a reactive moiety capable of reacting with a reactive group in a target so as to form a linkage between the heterobifunctional polymer and the target. A target is defined below. Examples of Q include, but are not limited to, aldehydes, carboxylic acids, carbonate esters, hydrazides, N-succinimidyl esters, amines, isocyanates, alcohols, epoxide, 15 thiols, orthopyridyl disulfides, and sulfonate esters.

Typically, Q reacts with a reactive group on a target to form a stable linkage such that the heterobifunctional polymer of the invention is conjugated onto a target. A conjugate formed in this manner can be represented by the formula:



20

or




where Z, POLY, POLY' and W are as described above. L represents a stable linkage formed as a result of the reaction between Q and a reactive group on T as described below. Examples of the hydrolytically stable linkage L include, but are not limited to, 25 amide from the reaction of active esters with amine, urethane from the reaction of isocyanate with alcohol, urea from the reaction of isocyanate with amine, amine from the reaction of aldehyde with amine and a reducing agent, amine from the reaction of epoxide with amine, and sulfonamide from the reaction of sulfonate ester with amine.

30

T represents a target which is typically a molecule or an entity having a desirable function or property. For example, T can be a protein or a pharmaceutically effective agent. By forming a conjugate or hydrogel of the invention, a target T is in effect "loaded" onto a carrier and can be delivered into a desired location under the protection of the polymer backbone or the hydrogel matrix before it is released by hydrolytic breakdown of the unstable linkage W in the polymer or hydrogel.


Accordingly, a target T in this invention can be any substance to which it is desirable to link poly(alkylene oxide) or derivatives thereof. T must have a reactive group capable of reacting with the reactive moiety Q to form a stable linkage L. Examples of suitable Ts include, but are not limited to, proteins, carbohydrates, 5 lipids, hormones, oligonucleotides. Typically, T is a pharmaceutically effective agent. Examples of such substances include, but are not limited to, antibodies and fragments thereof; cytokines including, but not limited to interleukins (e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, and derivatives or fragments thereof), interferons (e.g., IFN-alpha, IFN-beta and IFN-gamma); growth 10 factors, including but not limited to colony stimulating factors, erythropoietins, haemopoietins, epidermal growth factors, platelet derived growth factors, transforming growth factors, amphiregulin, somatomedin-C, bone growth factor, fibroblast growth factors, insulin-like growth factors, heparin binding growth factors, tumor growth factors and other growth factors, platelet activating factors, macrophage 15 activation factors, and other activating factors; transcription factors; substances affecting blood clotting including but not limited to heparin, proteases and their pro-factors, clotting factors VII, VIII, IX, X, XI and XII, antithrombin III, protein C, protein S, streptokinase, urokinase, prourokinase, tissue plasminogen activator, fibrinogen, hirudin, other fibrinolytic/anticoagulant agents and other coagulation 20 factors; lipids including but not limited to phosphatidylethanolamine, phosphatidylserine, sphingosine, cholesterol and other steroids and derivatives thereof; nucleotides including but not limited to ribonucleotides, deoxyribonucleotides, nucleosides, oligonucleotides, DNA, and RNA; enzymes; vaccines; vitamins; antibiotics; and other pharmaceutically effective agents including 25 but not limited to antihelminthic agents, noradrenalin, alpha adrenergic receptor ligands, dopamine receptor ligands, histamine receptor ligands, GABA/benzodiazepine receptor ligands, serotonin receptor ligands, leukotrienes and tri-iodothyronine and other small effector molecules, doxorubicin, methotrexate and other cytotoxic agents and derivatives thereof.

30 When the hydrolytically unstable linkage W is situated within the poly(alkylene oxide) backbone of the heterobifunctional polymers or the conjugates of this invention, W can be formed by reacting two modified polymers having terminal reactive moieties as illustrated below:



In the above illustration, -W- represents the hydrolytically unstable weak linkage. X and Y represent the reactive moiety pairs as described above. Exemplary reactions are illustrated below where the reverse reactions illustrate hydrolytic reversibility:

5



where U is a reactive group on T.

15

The skilled artisan should recognize that when reference is made to an X moiety reacting with a Y moiety, or a Q group with a U group, additional reagents or steps may be employed according to commonly accepted chemical procedures and standards to achieve the desired linkage W or L as the case may be. There are many possible routes, too numerous to mention here, that could be taken and that should be readily apparent to the skilled artisan. For example, one of skill in the art can be expected to understand that when an alcohol and a carboxylic acid are reacted, the acid typically is converted to another form, the acid chloride, prior to reaction with alcohol. Several examples are demonstrated in the Examples below.

20 The heterobifunctional polymers and conjugates of this invention described above can be employed in polymerization reactions to form polymers and hydrogels.

25 Since the heterofunctional polymers and the conjugates of this invention all have an acrylate group, vinyl polymerization of each of the heterofunctional polymers or conjugates can be conducted by a method known in the art. Two or more compounds selected from the heterofunctional polymers and the conjugates of this invention can be copolymerized. Many methods of vinyl polymerization are generally known in the art and are useful in the present invention. Generally, when a conjugate is involved in the polymerization or copolymerization, conditions for the

polymerization reaction should be selected such that the target in the conjugate is not adversely affected. Suitable polymerization methods include, for example, redox initiation and photo initiation. Other suitable methods should be apparent to a skilled artisan once apprised of the present disclosure.

5 In accordance with another aspect of this invention, hydrogels can be prepared from the heterobifunctional polymers and conjugates, as well as the vinyl polymers by polymerization and/or crosslinking. As used herein, "hydrogel" is intended to mean gels produced by incorporating the soluble hydrophilic polymers (e.g., heterofunctional polymers and conjugates of this invention) into a chemically 10 crosslinked network or matrix so that addition of water produces an insoluble swollen gel. Crosslinks can be formed from the heterobifunctional polymers or conjugates themselves. However, typically, crosslinks are introduced by copolymerizing the heterobifunctional polymers or conjugates with a multiacrylate as a monomer. By 15 "multiacrylate" it is intended to mean a molecule having two or more acrylate groups so that it can form a crosslinking bridge in vinyl polymerization of the heterobifunctional polymers or conjugates of the present invention. Preferably, the multiacrylate used is a PEG multiacrylate, i.e., a PEG molecule having two or more acrylate groups therein. Exemplary examples of such PEG multiacrylate can be, e.g.,

20 or
 $\text{CH}_2=\text{CHCO}_2\text{-PEG-O-CH}_2\text{CO}_2\text{CH}(\text{CH}_3)\text{CH}_2\text{CONH-PEGO}_2\text{CCH=CH}_2$

However, many other multiacrylate monomers can also be used as is apparent to a skilled artisan apprised of this invention.

Typically, a hydrolytically degradable conjugate of this invention having a target therein is used in preparing the hydrogel of this invention. In this manner, the target is incorporated covalently into the hydrogel which can be used as a carrier for *in vivo* delivery or other applications. Thus, the hydrogels of the invention are particularly useful in drug delivery systems. By "drug" is meant any substance intended for the diagnosis, cure, mitigation, treatment, or prevention of disease in humans and other animals, or to otherwise enhance physical or mental well being. For example, hydrogels made from the crosslinked PEG polymeric structures of the invention can be used for wound dressings. Wound dressings can be used internally to provide dressings that degrade within the body over time.

In the hydrogel of this invention, the target material that is covalently linked to the hydrogel can be released in an aqueous environment by hydrolytic breakdown of the hydrolytically unstable linkage W. In order to control the rate of release of the target in the hydrogel, the unstable linkage W can be manipulated 5 during the preparation of the hydrogel. It has been discovered that the number of atoms, particularly alkylene groups, proximate to the hydrolyzable bond in W affects the hydrolysis rate of the hydrolyzable bond. For example, as the number of methylene group increases, the hydrolysis rate decreases.

For example, when W has the structure of:



where m ranges from 1 to 10, R₁ is selected from the group consisting of -CH₂-, -CH₂CH₂-, and -CH(CH₃)CH₂-, increasing the m value decreases the hydrolysis rate of esters and increases the time required for the gel to degrade. Typically, if m in the above example is 1, then the ester linkages of the gel will hydrolyze with a half life of 15 about 4 days at pH 7 and 37°C. If m is 2, then the half life of hydrolytic degradation of the ester linkages is about 43 days at pH 7 and 37°C. Phosphate esters, acetals, imines, and other hydrolytically unstable linkages can be similarly formed and the hydrolysis rate can be similarly controlled by controlling the number of methylene groups adjacent the hydrolytically unstable linkage.

20 In addition, in the hydrogel of the present invention, the release rate of the target from the hydrogel can also be controlled by varying the number x of the PEG acrylates linked to the target. The release rate of the target from the hydrogel is decreased when the number of PEG acrylates linked to the target is increased. Release rate is increased by decreasing the number.

25 In the hydrogel of this invention, a two-fold control of the target release rate is made possible: (1) by varying the number of atoms proximate to the hydrolyzable bond in the hydrolytically unstable linkage W; and (2) by controlling the number of the PEG acrylates linked to the target. As a result, the hydrogels of this invention can be designed to have a more precisely controlled target release rate, 30 which is useful in hydrogel applications, e.g., drug delivery.

The following examples are given to illustrate the invention, but should not be considered in limitation of the invention.

Example 1. Synthesis of $\text{CH}_2=\text{CHCO}_2\text{-PEG-OCH}_2\text{CO}_2\text{CH}(\text{CH}_3)\text{CH}_2\text{CO}_2\text{NS}$
(NS= N-succinimidyl)

Example 2. Modification of proteins

Example 3. Preparation of gels

5 Example 4. Release of proteins from gels




EXAMPLES

EXAMPLE 1

PREPARATION OF

10 $\text{CH}_2=\text{CHCO}_2\text{-PEG-OCH}_2\text{CO}_2\text{CH}(\text{CH}_3)\text{CH}_2\text{CO}_2\text{NS}$

REACTION SCHEME:



20 a.) Preparation of BzO-PEG-OCH₂CO₂-CH(CH₃)CH₂CO₂H

BzO-PEG-OCH₂CO₂H (MW=3400, 15 g, 4.4 mmole) was azeotropically dried with 60 ml of toluene under N₂. After two hours, the solution was slowly cooled to room temperature. To this solution was added thionyl chloride (18 ml, 36 mmole). The resulting solution was stirred overnight, the solvent condensed by rotary evaporation, and the syrup dried *in vacuo* for about four hours over P₂O₅ powder. 3-hydroxybutyric acid (1.45 g, 13.5 mmole) was azeotropically dried with 70 ml of 1,4-dioxane, and then added to the dried BzO-PEG-OCH₂COCl. After the PEG acyl chloride had dissolved, 4.5 ml of dry triethylamine was injected

into the system and the solution was stirred overnight. The salt was removed by filtration and the filtrate was condensed on a rotary evaporator at 55°C and dried *in vacuo*. The crude product was then dissolved in 100 ml of distilled water and the pH of the solution was adjusted to 3.0. The aqueous phase was extracted three times with 5 a total of 80 ml of methylene chloride. The organic phase was dried over sodium sulfate, filtered, condensed on a rotary evaporator, and precipitated into 100 ml of ethyl ether. The product was collected by filtration and dried *in vacuo* at room temperature. Yield 14 g (93%). ^1H nmr (DMSO-d₆): δ 3.5 (br m, PEG), 2.58 (d, -PEGCOOCH(CH₃)CH₂COOH), 5.14 (h, -PEG-COOCH(CH₃)CH₂COOH), 1.21 (d, -PEGCOOCH(CH₃)CH₂COOH), 4.055 (s, PEGOCH₂COO), 4.49 (s, C₆H₅-CH₂-OPEG-), 7.33 (s+comp. mult., C₆H₅-CH₂-OPEG-).

10

b.) Preparation of HO-PEG-OCH₂CO₂-CH(CH₃)CH₂CO₂H

15 A solution of BzO-PEG-OCH₂CO₂-PEG-OCH(CH₃)CH₂CO₂H (8 g) in benzene (50 ml) was hydrogenolyzed with H₂ (2 atm) on 4 gram Pd/C (10%) at room temperature for 48 hours. The catalyst was removed by filtration, the solvent was condensed, and the solution was precipitated into ethyl ether. The product was collected by filtration and dried *in vacuo* at room temperature.

20 Yield: 6.6 gram (83%). ^1H nmr (DMSO-d₆): δ 3.5 (br m, PEG), 2.51 (d, PEGCO₂CH(CH₃)CH₂CO₂H), 5.16 (h, -PEG-CO₂CH(CH₃)CH₂CO₂H), 1.22 (d, -PEG-CO₂CH(CH₃)CH₂CO₂H), 4.06 (s, -PEGOCH₂CO₂PEG-).

c.) Preparation of CH₂=CHCO₂-PEG-OCH₂CO₂-CH(CH₃)CH₂CO₂H

25 HO-PEG-OCH₂CO₂CH(CH₃)CH₂CO₂H (3g, 0.88 mmole) was azeotropically distilled with 40 ml of toluene under N₂ until approximately 15 ml of solution remained. The solution was then cooled to room temperature under N₂ and 25 ml of methylene chloride and triethylamine (1.5 mmole) were added. The solution was cooled in an ice bath and acryloyl chloride (2 mmole) were added dropwise. After addition of acryloyl chloride, the ice bath was removed and the solution was 30 stirred at room temperature overnight. The methylene chloride was then partially removed under vacuum, the salt was removed by filtration, and the filtrate added to 100 ml of ether. The precipitated product was collected by filtration and dried *in vacuo*. The product was then dissolved in sodium acetate buffer (0.1M, pH 5.5),

stirred for half an hour, and extracted three times with methylene chloride. The organic phase was dried over sodium sulfate, filtered, condensed, and precipitated in 100 ml of ethyl ether. The precipitate was collected by filtration and dried *in vacuo* at room temperature. Yield 2.4 g (80%). ^1H nmr (DMSO-d₆): δ 3.5 (br m, PEG), 2.51 (d, $\text{CH}_2\text{CO}_2\text{H}$), 5.16 (h, -CH(CH₃)-), 1.22 (d, -CH(CH₃)-), 4.06 (s, -PEGOCH₂CO₂PEG-), 4.21 (t, -CO₂CH₂CH₂O-), 5.85-6.45 (m, CH₂=CH-).

d.) Preparation of CH₂=CHCO₂-PEG-OCH₂CO₂-CH(CH₃)CH₂CO₂NS

CH₂=CH-CO₂-PEG-OCH₂CO₂CH(CH₃)CH₂CO₂H (1.4 g, approx. 0.4 mmole) and N-hydroxysuccinimide (51 mg, 0.43 mmole) was dissolved in 30 ml of dry methylene chloride. To this solution was added dicyclohexylcarbodiimide (95 mg, 0.45 mmole) in 5 ml of dry methylene chloride. The solution was stirred under nitrogen overnight and the solvent removed by rotary evaporation. The resulting syrup was dissolved in 10 ml of dry toluene and the insoluble solid was removed by filtration. The filtrate was added to 100 ml of dry ethyl ether and the precipitated product was collected by filtration and dried *in vacuo* at room temperature.

Yield 0.94g (94%). ^1H nmr (DMSO-d₆): δ 3.5 (br m, PEG), 3.0-3.2 (m, -PEGCOOCH(CH₃)CH₂COONS), 5.26 (h, PEGCOOCH(CH₃)CH₂COONS), 1.3 (d, -PEGCOOCH(CH₃)CH₂COONS), 4.10 (s, -PEGOCH₂COO (CM)), 2.81 (s, NS), 4.21 (t, CH₂=CH-COO-CH₂CH₂O-PEG-, 4H), 5.85-6.45(m, CH₂=CHCOOPEG-).

EXAMPLE 2

Modification of Proteins

a) Modification of lucifer-yellow modified lysozyme

CH₂=CHCO₂-PEG-OCH₂CO₂-CH(CH₃)CH₂CO₂NS (19 mg, 5.5 mmole) was dissolved in 0.1 ml of water and 0.5 ml of lucifer-yellow modified lysozyme solution and (20 mg/ml) in borate buffer (0.1M, pH 8.0) was added. The solution was shaken gently on an auto-shaker at room temperature for 3 hours. Completion of the reaction was demonstrated by capillary electrophoresis. The solution was then stored at 4°C prior to release studies.

b) Modification of fluorescein isothiocyanate-Bovine serum albumin (FTIC-BSA):

5 $\text{CH}_2=\text{CHCO}_2\text{-PEG-OCH}_2\text{CO}_2\text{-CH(CH}_3\text{)CH}_2\text{CO}_2\text{NS}$ (9.3 mg, 2.7 mmole) was dissolved in 0.5 ml of deionized water and 1.5 ml of FITC-BSA solution (15 mg/ml) in boric buffer (0.1M, pH 8.0) was added. The solution was shaken gently on an auto-shaker at room temperature for 3 hours. Completion of the reaction was demonstrated by capillary electrophoresis. The solution was then stored at 4°C prior to release studies.

EXAMPLE 3

Preparation of Gels

10 a.) By Redox Initiation

15 A solution of (0.5 ml, 200 mg/ml in water of $\text{CH}_2=\text{CHCO}_2\text{-PEG-O-CH}_2\text{CO}_2\text{CH(CH}_3\text{)CH}_2\text{CONH-PEGO}_2\text{CCH=CH}_2$ or $\text{CH}_2=\text{CHCO}_2\text{-PEG-O-CH}_2\text{CO}_2\text{PEG-O}_2\text{CCH=CH}_2$, and 0.5 ml of buffered PEG acrylate-modified lucifer yellow lysozyme (Example 2a) solution (10 mg/ml, f and 20 ml of potassium persulfate ($\text{K}_2\text{S}_2\text{O}_8$, 100 mM) were mixed. To the solution was added 20 ml of iron sulfate (FeSO_4 , 100 mM). After rapid shaking, a gel formed in a few minutes.

20 A suitable buffer for this procedure is boric buffer (0.1 M) or phosphate buffer (<0.01M) with pH range of 6 to 8.

25 b.) By Photo Initiation

25 Difunctional PEG acrylate solution (0.5 ml, 400 mg/ml in water, $\text{CH}_2=\text{CHCO}_2\text{-PEG-O-CH}_2\text{CO}_2\text{CH(CH}_3\text{)CH}_2\text{CONH-PEGO}_2\text{CCH=CH}_2$ or $\text{CH}_2=\text{CHCO}_2\text{-PEG-O-CH}_2\text{CO}_2\text{PEG-O}_2\text{CCH=CH}_2$, 0.5 ml of buffered (pH 7) PEG acrylate-modified FITC-BSA solution (Example 2b) and 100 ml of 2,2-dimethoxy-2-phenyl-acetophone solution (10 mg/ml in ethanol) were mixed. The solution was exposed to UV radiation at a wavelength of 360 nm and the gel formed in about 10 minutes.

EXAMPLE 4

Release of Proteins from the Gels

The release of lucifer yellow lysozyme was monitored using a flow UV spectrophotometer at 428 nm and 37°C in 0.1 M phosphate buffer (pH 7). Release profiles for two experiments are shown in Figure 1.

Although the foregoing invention has been described in some detail by 5 way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

THAT WHICH IS CLAIMED IS:

1. A heterobifunctional polymer comprising:
a poly(alkylene oxide) backbone;
5 a first terminus comprising an acrylate group;
a second terminus comprising a target or a reactive moiety capable of coupling to a target; and
a hydrolytically degradable linkage for releasing said target upon hydrolysis.
- 10 2. A compound represented by the formula:
$$\text{CH}_2=\text{CZ-CO}_2\text{-POLY-W-POLY'-Q}$$
where
Z represents H or alkyl;
POLY and POLY' are poly(alkylene oxide) groups that can be the
15 same or different and are represented by the formula $-(\text{CH}_2\text{CHRO})_n\text{-CH}_2\text{CHR-}$ in which R is H or alkyl, and n ranges from about 10 to about 4000;
Q represents a functional group; and
W represents a hydrolytically unstable linkage.
- 20 3. A compound represented by the formula:
$$\text{CH}_2=\text{CZ-CO}_2\text{-POLY-W-Q}$$
where
Z represents H or alkyl;
POLY is poly(alkylene oxide), represented by the formula
 $-(\text{CH}_2\text{CHRO})_n\text{-CH}_2\text{CHR-}$ in which R is H or alkyl, and n ranges from about 10 to
25 about 4000;
Q represents a functional group; and
W represents a hydrolytically unstable linkage.
4. The compound of either of Claims 2 or 3, wherein POLY and POLY' are poly(ethylene glycol).
- 30 5. The compound of either of Claims 2 or 3, wherein W comprises a hydrolyzable covalent bond selected from the group consisting of esters, orthoesters, imines, acetals, peptide bonds, and disulfides.

6. The compound of either of Claims 2 or 3, wherein W has a

structure of:




where m ranges from 1 to 10, and R₁ is -CH₂-, -CH₂CH₂- or -CH(CH₃)CH₂-, or W has

5 the structure -O-(CH₂)_m-CO₂-.

7. The compound of either of Claims 2 or 3, wherein Q is selected from the group consisting of aldehydes, carboxylic acids, active esters, active carbonates, sulfonate esters, amines, hydrazides, orthopyridyl disulfides, and thiols.

8. A conjugate having a formula of:



where

Z is H or an alkyl group;

POLY and POLY' are poly(alkylene oxides) comprising groups that

can be the same or different and are represented by the formula

15 -(CH₂CHRO)_n-CH₂CHR- in which R is H or alkyl, and n ranges from about 10 to about 4000;

W represents a hydrolytically unstable linkage;


L is hydrolytically stable linkage;

x is an integer of 1-10; and

20 T is a target molecule.

9. The conjugate of Claim 7, wherein R is H.

10. The conjugate of Claim 7, wherein W has the structure of:



where m ranges from 1 to 10, R₁ is selected from the group consisting of -CH₂-, -

25 CH₂CH₂-, and -CH(CH₃)CH₂- or W has the structure -O-(CH₂)_m-CO₂-.

11. The conjugate of Claim 7, wherein T is selected from the group consisting of proteins, polysaccharides, oligonucleotides, lipids, vitamins, hormones, or small molecule pharmaceuticals.

12. A compound having the following structure:



where

Z represents H or alkyl;

POLY is a poly(alkylene oxide) represented by the formula

$-(\text{CH}_2\text{CHRO})_n\text{CH}_2\text{CHR}-$ in which R is H or alkyl, and n ranges from about 10 to about 4000;


5 Q represents a functional group; and

W represents a hydrolytically unstable linkage.

13. The compound of Claim 11, wherein POLY is poly(ethylene glycol).

14. The compound of Claim 11, wherein W comprises a hydrolyzable covalent bond selected from the group consisting of esters, orthoesters, imines, acetals, peptide bonds, and disulfides.


15. The compound of Claim 11, wherein W has the structure of:



where m ranges from 1 to 10 and R₁ is -CH₂-, -CH₂CH₂-, or -CH(CH₃)CH₂- or W has the structure -O-(CH₂)_m-CO₂-.

16. The compound of Claim 11, wherein Q is selected from the group consisting of aldehydes, carboxylic acids, active esters, active carbonates, sulfonate esters, amines, hydrazides, orthopyridyl disulfides, N-succinimidyl, and thiols.

20 17. A conjugate having the following structure:



where

Z represents H or alkyl;

POLY is a poly(alkylene oxide) comprising a group represented by the formula $-(\text{CH}_2\text{CHRO})_n\text{CH}_2\text{CHR}-$ in which R is H or alkyl, and n ranges from about 10 to about 4000;


W represents a hydrolytically unstable linkage;

L is a hydrolytically stable linkage;

x is an integer from 1 to 10; and

30 T is a target molecule.

18. A polymer selected from the group consisting of compounds represented by the formula:



5

where

Z is H or an alkyl group;

10 POLY and POLY' are poly(alkylene oxides) that can be the same or different and are represented by the formula $-(\text{CH}_2\text{CHRO})_n\text{-CH}_2\text{CHR-}$ in which R is H or alkyl, and n ranges from about 10 to about 4000;

W represents a hydrolytically unstable linkage;


Q represents a functional group;

L is hydrolytically stable linkage;

15 x is an integer of 1-10; and

T is a target molecule.

19. The polymer composition of Claim 17, wherein W has the structure of:




20 where m ranges from 1 to 10, R₁ is selected from the group consisting of -CH₂-, -CH₂CH₂-, and -CH(CH₃)CH₂- or W has the structure of -O-(CH₂)_m-CO₂-.

20. The polymer composition of Claim 17, wherein T is a protein.

21. The polymer composition of Claim 17, wherein R is H.

22. A hydrogel comprising a co-polymerization product of a 25 multiacrylate and at least one compound selected from the group consisting of compounds represented by the formula:



30

where

Z is H or an alkyl group;

POLY and POLY' are poly(alkylene oxides) that may be the same or different and are represented by the formula -(CH₂CHRO)_n-CH₂CHR- in which R is H or alkyl, and n ranges from about 10 to about 4000;

W represents a hydrolytically unstable linkage;

5 Q represents a functional group;

L is hydrolytically stable linkage;

x is an integer of 1-10; and


T is a target molecule.

23. The hydrogel of Claim 21, wherein said multiacrylate is
10 selected from the group consisting of PEG diacrylates and N-vinylpyrrolidone.

24. The hydrogel of Claim 22, wherein said PEG diacrylate is
CH₂=CHCO₂-PEG-O-CH₂CO₂CH(CH₃)CH₂CONH-PEGO₂CCH=CH₂ or
CH₂=CHCO₂-PEG-O-CH₂CO₂PEG-O₂CCH=CH₂.

25. The hydrogel of Claim 21, wherein T is a protein.

1/1



RELEASE PROFILE OF LUCIFER-YELLOW LYSOZYME
FROM A PEG-ACRYLATE HYDROGEL

FIG. 1.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/US 99/00594

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 5648506	A 15-07-1997	AU 4406793	A	30-12-1993	
		WO 9324476	A	09-12-1993	
WO 9620012	A 04-07-1996	US 5554730	A	10-09-1996	
EP 0658585	A 21-06-1995	DE 4342154	A	14-06-1995	
		AU 696532	B	10-09-1998	
		AU 8032794	A	15-06-1995	
		CA 2137748	A	11-06-1995	
		JP 7206927	A	08-08-1995	
		US 5571844	A	05-11-1996	

MicroPatent® Document Availability and Pricing

Before you submit your order

- Check all patent numbers.
- If this is a multipart order, check all parts.
- Choose delivery options separately for Standard and Special Collections.

Submit Order

for the selected patents below.

Standard Collection Patents

To preview the front page of a patent document, select one of the **Preview** links to the right of the patent number: **MP** for viewing in the MicroPatent® PatentImage Viewer, **TIFF** for viewing in a multi-page TIFF viewer, or **PDF** for viewing in a PDF viewer such as Adobe® Acrobat. Previews are FREE if you order the corresponding patents within twenty-four hours. Otherwise there is a charge of \$1.50 per preview.

Acrobat® users please select one of the PDF-format delivery options following.

Delivery options: *Connecticut residents must add 6% sales tax.*

us6075137 [50165/004001], 13 pages
Human urotensin II

Preview: [MP](#) [TIFF](#) [PDF](#)

us6005074 [50165/004001], 15 pages
Cloning of human GPR14 receptor

Preview: [MP](#) [TIFF](#) [PDF](#)

wo9940192A1 [50165/004001], 64 pages
HUMAN RECEPTOR GPR14, AND A METHOD OF FINDING AGONIST AND ANTAGONIST TO HUMAN AN

Preview: [MP](#) [TIFF](#) [PDF](#)[Return to PatentWeb top page](#)[Return to MicroPatent home page](#)*info@micropat.com*

PatentWeb™ Document Delivery Order

The requested patent documents were not found or were not deliverable as requested.

Please back up and try again.

You may contact *tech_support@micropat.com* for further information.
Sorry for the inconvenience.

PatentWeb™ Document Delivery Order

The requested patent documents were not found or were not deliverable as requested.

Please back up and try again.


You may contact *tech_support@micropat.com* for further information.
Sorry for the inconvenience.

C. MARQUARDT.

Whiffle-tree.

No. { 3,023. }
34,027. {

Patented Dec. 24, 1861.



Witnesses
J. W. Combs
A. E. Beach

Inventor
L. Marquardt
By Lummis & Co
Atay

UNITED STATES PATENT OFFICE.

CONRAD MARQUARDT, OF RHINEBECK, NEW YORK, ASSIGNOR TO MARIA L. MARQUARDT, OF SAME PLACE.

IMPROVEMENT IN WHIFFLETREE ATTACHMENTS.

Specification forming part of Letters Patent No. 34,027, dated December 24, 1861.

To all whom it may concern:

Be it known that I, CONRAD MARQUARDT, of Rhinebeck, in the county of Dutchess and State of New York, have invented a new and useful Improvement in Whiffletree Attachments for Two-Horse Vehicles; and I do hereby declare that the following is a full, clear, and exact description of the same, reference being had to the accompanying drawings, making a part of this specification, in which—

Figure 1 is a plan or top view of my invention; and Fig. 2, a transverse section of the same, taken in the line $x x$, Fig. 1.

Similar letters of reference indicate corresponding parts in the two figures.

This invention relates to a novel means employed for attaching the whiffletrees to the doubletree, as hereinafter fully shown and described, whereby the whiffletrees may be readily adjusted on the doubletree nearer to or farther from its bolt, and the draft regulated for either horse, as occasion may require.

It is quite frequently the case that one horse of a team is capable of drawing more than the other, and in the ordinary whiffletree attachment the stronger horse pulls against or has a tendency to draw back the weaker one, and the efficiency of the team is greatly reduced thereby.

The object of the within-described invention is to obviate this difficulty, and to this end I have the back edge of the doubletree provided with notches or racks at each end, in which the whiffletree clasps or links are fitted and retained therein by a spring, substantially as hereinafter described.

To enable those skilled in the art to fully understand and construct my invention, I will proceed to describe it.

A represents a doubletree, which may be of the usual form and dimensions, and B B are two racks or notched metal bars, which are secured to the back edge of the doubletree—one near each end—as shown in Fig. 1.

To the front edge of the whiffletree there are attached metal plates C C, said plates being directly in front of the racks B B.

D D represent whiffletrees, which may also be of the usual form and length. Each whiffletree has a link E attached to it near its center. These links are of rectangular form, and they are attached to the whiffletrees by being fitted in eyes or loops a, which are secured to the whiffletrees. These links E E are placed on the doubletree, the back ends of the links fitting in the racks B. The links are retained in the racks B B by means of springs F F, which may be of spiral form, and placed on pins b, attached to the back edges of the whiffletrees. The springs F bear against the plates C at the front edge of the doubletree and have a tendency to keep the whiffletrees forced outward from the doubletree, and consequently keep the links E in the racks. By this arrangement it will be seen that the whiffletrees may be readily shifted on the doubletree, so that the links may fit in any of the notches of the racks and the draft-connection of either horse regulated as desired. It will be seen that when the vehicle is being drawn along the links E will be retained in the racks by the pull of the whiffletrees, but when the draft movement ceases the springs F perform that function.

The invention is extremely simple and will not augment in an appreciable degree the usual cost of construction.

Having thus described my invention, what I claim as new, and desire to secure by Letters Patent, is—

Attaching or connecting the whiffletrees D D to the doubletree A by means of the links E E, racks B B, and the springs F F, arranged substantially as set forth.

CONRAD MARQUARDT. [L. S.]

Witnesses:

H. T. VAN KEUREN,
JOHN R. RYNDERS.